drugset
drugset / Trial / NCT02714062

A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents

NCT02714062 ↗

Phase 4 Completed 42 enrolled VIVUS LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective of this study is to describe the pharmacokinetic profiles of VI-0521 in obese adolescents.

Timeline

Start
2016-03
Primary completion
2016-10
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject VI-0521 Unknown — Oral

Indications

obesity, hyperphagia, and developmental delay